// App-Quantinova.ai

82 : EP-104IAR − A Potential New Treatment for Knee Osteoarthritis: Prolonged Local Exposure of Fluticasone Propionate with No Impact on Cartilage Health.

Researchers

Presenter

  • Murray Webb

Principal Investigators

  • N/A

Medical Centers

  • Eupraxia Pharmaceuticals Inc., Victoria, British Columbia, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Desmoglein-3

Drug/Treatment

  • Fluticasone propionate

  • Fluticasone furoate

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved